Hi,
I am trying to see what is the status of investigation of Olaparib, a PARP inhibitor approved for ovarian cancer, in IDH1 mutated high grade glioma. There is a strong rationale for PARP inhibition in these type of tumors and preliminary results in 2017 made the news. I saw some combination studies ongoing in US and UK, but not sure if the company is still working on this.....
Also virtual ASCO is coming up. Do people have to pay to registration?
thank you.
I am trying to see what is the status of investigation of Olaparib, a PARP inhibitor approved for ovarian cancer, in IDH1 mutated high grade glioma. There is a strong rationale for PARP inhibition in these type of tumors and preliminary results in 2017 made the news. I saw some combination studies ongoing in US and UK, but not sure if the company is still working on this.....
Also virtual ASCO is coming up. Do people have to pay to registration?
thank you.
Comment